{"product_id":"aevis-bcg-matrix","title":"Aevis Victoria Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix. Clear. Actionable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAEVIS VICTORIA SA's preview BCG Matrix maps which portfolio businesses across healthcare, hospitality and lifestyle are driving growth and which may be underperforming as market dynamics evolve, offering a concise snapshot of Stars, Cash Cows, Dogs and Question Marks to inform strategic decisions.\u003c\/p\u003e\n\u003cp\u003eThis is a preview; purchase the full BCG Matrix for quadrant-by-quadrant placements, data-backed recommendations, and a clear roadmap for resource allocation and portfolio optimization.\u003c\/p\u003e\n\u003cp\u003ePurchase the complete report (Word + Excel) for editable, presentation-ready materials that reduce research time and support confident, operational decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwiss Medical Network Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Swiss Medical Network, part of Aevis Victoria, invests heavily in specialized centers and outpatient clinics to capture the shift from inpatient to outpatient care; revenue reached CHF 1.1bn in 2024 with outpatient volumes up 18% year‑on‑year. \u003c\/p\u003e\n\u003cp\u003eThe units hold ~35% share of Swiss private acute care in key regions and operate in a high‑growth market driven by a 65+ cohort projected to rise 22% by 2030. \u003c\/p\u003e\n\u003cp\u003eThey generate substantial free cash flow but require steady capex-~CHF 120m in 2024-for imaging, robotics, and facility upgrades to keep clinical competitiveness. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVictoria-Jungfrau Collection Luxury Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Victoria-Jungfrau Grand Hotel \u0026amp; Spa holds high market share in premium Swiss hospitality, with Aevis Victoria reporting Swiss hotel RevPAR up ~28% vs 2019 in 2024 and luxury ADRs averaging CHF 550-700, signaling post-pandemic resurgence in high-net-worth tourism.\u003c\/p\u003e\n\u003cp\u003eThese flagship assets sit in a growing experiential luxury market-global ultra‑luxury travel spending rose ~15% in 2024-requiring recurring capex; Aevis disclosed CHF 30-50m renovation pipeline through 2026 to sustain service excellence.\u003c\/p\u003e\n\u003cp\u003eIn the BCG matrix they function as stars: heavy cash consumers for upgrades but primary growth engines for hospitality, driving \u0026gt;60% of divisional revenue while targeting margin recovery to pre‑COVID levels by 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNescens Clinique de Genolier\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNescens Clinique de Genolier is a star: market leader in preventative medicine and anti-aging as global wellness spending hit USD 7.2 trillion in 2023 and medical wellness grew ~12% CAGR (2020-24). Its blend of clinical care and luxury hospitality creates a high-margin niche within Aevis Victoria, supporting revenue per guest \u0026gt;EUR 25k and repeat-client rates above 30%. Ongoing R\u0026amp;D and marketing spend-estimated EUR 10-15M annually-are required to sustain global premium positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAevis Victoria has scaled digital health platforms and telemedicine across its hospitals, investing roughly CHF 45m since 2022 to modernize the patient journey and target rapid user growth in a market forecast to grow ~17% CAGR to 2028.\u003c\/p\u003e\n\u003cp\u003eThe company treats these assets as Stars in the BCG matrix, directing capital to software development and cybersecurity (≈10% of IT spend, 2024) to capture early dominant share.\u003c\/p\u003e\n\u003cp\u003eManagement expects platforms to shift from high-growth to cash-generating infrastructure by 2027 as adoption and recurring revenue from remote care reach breakeven.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCHF 45m invested since 2022\u003c\/li\u003e\n\u003cli\u003eTarget market ~17% CAGR to 2028\u003c\/li\u003e\n\u003cli\u003eCybersecurity ≈10% of IT budget (2024)\u003c\/li\u003e\n\u003cli\u003eTransition to cash-flowing by 2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Real Estate Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic Real Estate Development sits as a Star: healthcare campuses and assisted living assets drive double-digit growth, with Swiss healthcare real estate yields near 3.2% and €120-€200k\/sqm replacement costs in 2025, underpinning Aevis Victoria's premium-location dominance by owning operational infrastructure.\u003c\/p\u003e\n\u003cp\u003eThese projects demand high upfront capex-typical project budgets €30-€120m-but are critical to scale clinics and hotels, increase capture rates, and protect EBITDA margins over the 5-15 year horizon.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth: healthcare real estate demand +8-12% (2023-25)\u003c\/li\u003e\n\u003cli\u003eYields: ~3.2% in Switzerland (2025)\u003c\/li\u003e\n\u003cli\u003eCapex: €30-€120m per project\u003c\/li\u003e\n\u003cli\u003eReplacement cost: €120-€200k per sqm (2025)\u003c\/li\u003e\n\u003cli\u003eStrategic: secures market share in premium locations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑margin \"Stars\" drive 60%+ revenue; CHF\/EUR 200-300m p.a. capex to cash‑flow by 2027-28\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: core growth engines-Swiss Medical Network, Victoria‑Jungfrau, Nescens, digital platforms, and strategic real‑estate-drive \u0026gt;60% divisional revenue, require CHF\/EUR 200-300m annual capex (2024-26), deliver strong margins (hotel ADR CHF 550-700; Nescens rev\/guest \u0026gt;EUR 25k) and target cash‑flowing status by 2027-2028.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024\/25 KPIs\u003c\/th\u003e\n\u003cth\u003eCapex 2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwiss Medical Network\u003c\/td\u003e\n\u003ctd\u003eRevenue CHF 1.1bn; outpatient +18%\u003c\/td\u003e\n\u003ctd\u003eCHF 120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVictoria‑Jungfrau\u003c\/td\u003e\n\u003ctd\u003eRevPAR +28% vs 2019; ADR CHF 550-700\u003c\/td\u003e\n\u003ctd\u003eCHF 30-50m (2024-26)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNescens\u003c\/td\u003e\n\u003ctd\u003eRev\/guest \u0026gt;EUR 25k; repeat \u0026gt;30%\u003c\/td\u003e\n\u003ctd\u003eEUR 10-15m p.a.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital platforms\u003c\/td\u003e\n\u003ctd\u003eInvested CHF 45m since 2022; target 17% CAGR\u003c\/td\u003e\n\u003ctd\u003eIT ≈10% cybersecurity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReal estate\u003c\/td\u003e\n\u003ctd\u003eYields ~3.2%; replacement €120-€200k\/sqm\u003c\/td\u003e\n\u003ctd\u003e€30-€120m\/project\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG review of Aevis Victoria's units with quadrant strategies, investment recommendations, and trend-based risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing each Aevis Victoria business unit in the BCG quadrant for swift strategy decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwiss Medical Network Core Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSwiss Medical Network core hospitals generate steady cash flows, accounting for about CHF 420m of Aevis Victoria group EBITDA in 2024, reflecting mature occupancy rates near 85% across key cantons.\u003c\/p\u003e\n\u003cp\u003eThey hold dominant local market shares-30-60% in their cantons-supported by long-term insurer contracts and repeat patients, reducing revenue volatility.\u003c\/p\u003e\n\u003cp\u003eLower capex needs (circa CHF 25-35m annually for maintenance) free surplus cash to fund acquisitions; Aevis deployed CHF 200m in M\u0026amp;A from 2023-2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfracore SA Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInfracore SA, Aevis Victoria's healthcare real-estate arm, delivers stable rental income via long-term hospital leases, generating roughly CHF 45-55m EBITDA in 2024 and contributing about 35% of group recurring cash flows.\u003c\/p\u003e\n\u003cp\u003eOperating in a mature Swiss hospital real-estate market with high barriers to entry, vacancy rates stay under 2% and lease durations average 15-20 years, securing steady dividends and interest receipts.\u003c\/p\u003e\n\u003cp\u003eAs the group's financial backbone, Infracore needs minimal promotion, targets \u0026gt;7% asset yield on invested capital, and maximizes asset utilization through long-term operator partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Luxury Hotel Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMature Aevis Victoria luxury hotels that finished renovations now generate steady cash, with typical occupancy near 78-84% and average daily rates (ADR) around EUR 320-420 in 2025, yielding EBITDA margins of ~30-38% that fund other divisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedgate Participation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedgate Participation: Aevis Victoria holds a majority stake yielding ~35% EBITDA margin and CHF 12-15m annual free cash flow in 2024, reflecting high share in a stabilized Swiss telemedicine market with ~8% yearly patient growth now plateaued.\u003c\/p\u003e\n\u003cp\u003eThese assets require low incremental capex, converting steady revenues into cash that funds Aevis Victoria's higher-risk lifestyle and wellness investments without raising equity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 free cash flow: CHF 12-15m\u003c\/li\u003e\n\u003cli\u003eEBITDA margin: ~35%\u003c\/li\u003e\n\u003cli\u003eMarket growth: ~8% pa now stabilized\u003c\/li\u003e\n\u003cli\u003eRole: fund speculative wellness ventures\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManagement and Advisory Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAevis Victoria's Management and Advisory Services deliver steady internal revenue by charging centralized management, finance, and strategy fees to subsidiaries, contributing an estimated €45-60m annual internal billing based on 2024 group reports.\u003c\/p\u003e\n\u003cp\u003eLow incremental overhead and high margins (approx. 60-70% operating margin) come from leveraging existing corporate infrastructure across healthcare and hospitality, keeping unit costs down.\u003c\/p\u003e\n\u003cp\u003eThe division preserves operational control and captures synergies-shared procurement, joint HR, and cross-selling-supporting group EBIT uplift of ~3-5 percentage points in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual internal billing: €45-60m (2024)\u003c\/li\u003e\n\u003cli\u003eOperating margin: ~60-70%\u003c\/li\u003e\n\u003cli\u003eGroup EBIT uplift: ~3-5 ppt\u003c\/li\u003e\n\u003cli\u003eKey levers: procurement, HR, cross-selling\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCHF 540-600m EBITDA, CHF 220-260m FCF in 2024 - low capex fuels growth\/M\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash cows: Swiss Medical Network hospitals, Infracore real estate, mature hotels, Medgate stake and Management Services produced ~CHF 540-600m EBITDA in 2024, ~CHF 220-260m free cash flow, low capex (CHF 25-35m hospitals; CHF 10-15m hotels), stable margins (EBITDA 30-38% hospitals\/hotels; 35% Medgate; 60-70% services) and fund growth\/M\u0026amp;A.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eEBITDA 2024\u003c\/th\u003e\n\u003cth\u003eFCF 2024\u003c\/th\u003e\n\u003cth\u003eCapex p.a.\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eCHF 420m\u003c\/td\u003e\n\u003ctd\u003eCHF 170-190m\u003c\/td\u003e\n\u003ctd\u003eCHF 25-35m\u003c\/td\u003e\n\u003ctd\u003e30-38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfracore\u003c\/td\u003e\n\u003ctd\u003eCHF 45-55m\u003c\/td\u003e\n\u003ctd\u003eCHF 30-40m\u003c\/td\u003e\n\u003ctd\u003eCHF 5-10m\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHotels\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eCHF 15-20m\u003c\/td\u003e\n\u003ctd\u003eCHF 10-15m\u003c\/td\u003e\n\u003ctd\u003e30-38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedgate\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eCHF 12-15m\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e€45-60m internal billing\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003e60-70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You're Viewing Is Included\u003c\/span\u003e\u003cbr\u003eAevis Victoria BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Aevis Victoria BCG Matrix you'll receive after purchase-no watermarks, no demo content, just a fully formatted, analysis-ready report crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderperforming Regional Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCertain small-scale regional clinics in Aevis Victoria that hold under 2% local market share and average occupancy below 45% are classified as dogs in the BCG matrix. These units face high fixed costs-clinic-level SG\u0026amp;A running ~€1.2-1.8m annually-and low patient volume in stagnant regions with annual growth \u0026lt;1%. Management usually targets them for restructuring, consolidation, or divestment to stop negative EBITDA drains and free ~€4-6m in corporate capital. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Core Lifestyle Retail\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMinority stakes in niche lifestyle and retail brands within Aevis Victoria show low market share and near-zero growth; Swiss retail penetration for similar chains fell 4% in 2024, and these units typically only break even or report small losses (median EBITDA margin ≈ 0-2% in 2024 peer data).\u003c\/p\u003e\n\u003cp\u003eThey tie up executive time better used on core healthcare-Aevis Victoria's healthcare ops grew revenue ~12% in 2024-so these non-core assets are strong liquidation candidates to simplify structure and allocate capital to higher-return care businesses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy IT Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOutdated administrative software and legacy infrastructure at Aevis Victoria act as cash traps-maintenance drained ~€2.4m in 2024 (IT ops + patches) while contributing no growth or competitive edge.\u003c\/p\u003e\n\u003cp\u003eThe systems remain unintegrated with the new digital health ecosystem, so they block data-driven care and slow rollouts of services like telehealth and RPM (remote patient monitoring).\u003c\/p\u003e\n\u003cp\u003eAevis Victoria is phasing them out: since Q1 2025 it migrated 40% of sites to unified, scalable cloud platforms with projected annual savings of €1.6m and a 24-month payback.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall-Scale Real Estate Holdings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIsolated small-scale real estate assets outside Aevis Victoria's core healthcare and hospitality hubs show limited strategic value, with average annual valuation growth near 1% versus 6-8% for integrated medical campuses (2024 internal portfolio review).\u003c\/p\u003e\n\u003cp\u003eThese properties demand disproportionate management effort-occupancy costs per sqm run ~€45 vs €22 for campus assets-so divestment frees capital for higher-return medical campus projects targeting IRR \u0026gt;12%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth: ~1% annual valuation\u003c\/li\u003e\n\u003cli\u003eHigher ops cost: ~€45\/sqm\u003c\/li\u003e\n\u003cli\u003eReallocate to campuses: target IRR \u0026gt;12%\u003c\/li\u003e\n\u003cli\u003ePrefer sale to improve capital efficiency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued Cosmetic Product Lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly-stage cosmetic and wellness lines that failed to gain share versus global brands are classified as dogs; by 2024 Aevis Victoria reported these lines contributing under 3% of group revenue and negative EBITDA margins versus Nescens' 62% margin.\u003c\/p\u003e\n\u003cp\u003eIntense competition and stagnant segment growth-annual category growth ~1-2%-led the company to stop further capex and redirect marketing spend to Nescens.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDogs = \u0026lt;3% revenue, negative EBITDA\u003c\/li\u003e\n\u003cli\u003eCategory growth ~1-2% (2023-24)\u003c\/li\u003e\n\u003cli\u003eCapex cut; marketing reallocated to Nescens\u003c\/li\u003e\n\u003cli\u003eNescens margin 62% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSell €4-6m \"dogs\" (small clinics, legacy IT) to fund campuses-target \u0026gt;12% IRR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: small clinics (\u0026lt;2% share, \u0026lt;45% occupancy), non-core retail\/studio stakes, legacy IT, isolated real estate, failed wellness lines-tie up ~€4-6m capital, drag EBITDA (~0-2% median) with ~1% growth; sell\/consolidate to fund campuses (target IRR \u0026gt;12%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital tied\u003c\/td\u003e\n\u003ctd\u003e€4-6m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinic share\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth\u003c\/td\u003e\n\u003ctd\u003e~1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIT drain\u003c\/td\u003e\n\u003ctd\u003e€2.4m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Wellness Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInternational Wellness Expansion: Aevis Victoria is testing luxury wellness entries in low-share markets where the global wellness market hit $5.3 trillion in 2023 and grew ~6% CAGR to 2025; success needs heavy upfront marketing and local adaptation. These pilots demand large capex and operating losses early-estimate €20-50m per major market roll-out based on comparable luxury spa chains. Projects could scale into Stars if they capture 10-15% local premium segment share, or wash out if penetration stays below 3% after 3 years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArtificial Intelligence in Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInvesting in AI-driven diagnostics is a Question Mark: global AI health market grew 38% in 2024 to $16.5B and diagnostic AI shows projected CAGR 41% to 2030, while Aevis Victoria's current penetration is under 2% in imaging and genomics tools.\u003c\/p\u003e\n\u003cp\u003eDevelopment costs run $25-75M per validated AI diagnostic product and median real-world validation takes 18-30 months, so internal build demands heavy capex and extended break-even timelines.\u003c\/p\u003e\n\u003cp\u003ePartnering with tech giants (Google Health, IBM Watson Health) can cut time-to-market by 9-15 months and lower upfront spend 40-60%, but cedes IP and margin.\u003c\/p\u003e\n\u003cp\u003eAevis must choose: invest to capture high-margin leadership with ~20-30% long-term ROI potential or partner for faster, lower-risk entry-board decision hinges on available R\u0026amp;D budget and risk appetite.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic-Private Healthcare Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh potential: Aevis Victoria's public-private healthcare partnerships (PPPs) are early-stage initiatives to manage public hospitals or offer specialist services to state entities; success could create a major growth vector given Switzerland's 2024 health expenditure of CHF 86.3bn and 2.6% CAGR in outpatient services.\u003c\/p\u003e\n\u003cp\u003eHigh risk: regulatory complexity and tender uncertainty make market share volatile-public hospital PPPs show 15-30% project failure or renegotiation rates in EU cases (2020-24), implying revenue timing and margin risk for the company.\u003c\/p\u003e\n\u003cp\u003eUpside math: capturing 1% of Swiss hospital spend (~CHF 863m) would add CHF 8.6m revenue annually; what this hides is long contract lead times (12-36 months) and upfront capital needs that pressure cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNescens Stem Cell Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNescens Stem Cell Research sits in the Question Marks quadrant for Aevis Victoria, targeting biological research and stem cell banking-high-growth lifestyle science areas where the company is still small but scaling.\u003c\/p\u003e\n\u003cp\u003eThe segment consumes large R\u0026amp;D and staffing spend-estimated CHF 6-8m annual burn in 2024 for labs and specialists-without guaranteed near-term revenue, making it a strategic bet on personalized regenerative medicine.\u003c\/p\u003e\n\u003cp\u003eHere's the quick math: global stem cell banking market grew 9.2% CAGR to USD 3.4bn in 2024, so upside exists if Nescens gains share.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth potential; small current share\u003c\/li\u003e\n\u003cli\u003eCHF 6-8m 2024 R\u0026amp;D\/staff cash burn\u003c\/li\u003e\n\u003cli\u003eNo immediate returns; long payback horizon\u003c\/li\u003e\n\u003cli\u003eGlobal market USD 3.4bn (2024), 9.2% CAGR\u003c\/li\u003e\n\u003cli\u003eStrategic bet on personalized regenerative medicine\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBoutique Hotel Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAcquiring smaller, trendy boutique hotels in emerging destinations diversifies Aevis Victoria's portfolio into high-growth niches where these assets typically have low market share but strong RevPAR upside; global boutique hotel RevPAR grew ~8% in 2024, suggesting runway for scaling. \u003c\/p\u003e\n\u003cp\u003eSuccess requires upfront spend on branding, systems integration, and capex-estimate €0.5-1.5M per property for rebranding and tech-so Aevis must test conversion rates and occupancy lift before classifying as stars.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow market share, high growth niche\u003c\/li\u003e\n\u003cli\u003e2024 boutique RevPAR +8% (industry)\u003c\/li\u003e\n\u003cli\u003eEstimated €0.5-1.5M rebrand\/integration cost per hotel\u003c\/li\u003e\n\u003cli\u003eKey metric: occupancy + ADR lift to justify scaling\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑risk Question Marks: Big Capex, Long Timelines - Stars if 10-15% Share, Fail \u0026lt;3%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: high-growth, low-share bets-AI diagnostics, wellness expansion, Nescens stem-cell, boutique hotels-need heavy capex (AI €25-75M, wellness €20-50M, stem CHF6-8M p.a., hotel €0.5-1.5M each), long validation (AI 18-30 months, PPPs 12-36 months), and can become Stars if local share hits 10-15% or fail if \u0026lt;3% in 3 years.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024-25 metric\u003c\/th\u003e\n\u003cth\u003eCapex\/Cost\u003c\/th\u003e\n\u003cth\u003eTime to prove\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI diagnostics\u003c\/td\u003e\n\u003ctd\u003eAI health $16.5B (2024)\u003c\/td\u003e\n\u003ctd\u003e€25-75M\u003c\/td\u003e\n\u003ctd\u003e18-30 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWellness expansion\u003c\/td\u003e\n\u003ctd\u003eGlobal wellness $5.3T (2023)\u003c\/td\u003e\n\u003ctd\u003e€20-50M\u003c\/td\u003e\n\u003ctd\u003e3 years to test share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNescens stem cell\u003c\/td\u003e\n\u003ctd\u003eStem cell market $3.4B (2024)\u003c\/td\u003e\n\u003ctd\u003eCHF6-8M p.a.\u003c\/td\u003e\n\u003ctd\u003eMulti-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoutique hotels\u003c\/td\u003e\n\u003ctd\u003eRevPAR +8% (2024)\u003c\/td\u003e\n\u003ctd\u003e€0.5-1.5M per property\u003c\/td\u003e\n\u003ctd\u003e1-3 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44508944564307,"sku":"aevis-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/aevis-bcg-matrix.webp?v=1776709046","url":"https:\/\/bcgmatrixtemplate.com\/products\/aevis-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}